Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 267

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 267
---
 |                |  — |     |              | — |     |                           |     160 |     |                                      |  — |     |                 |      — |   |     |                     | —        |   |     |                                       |    160 |   |
| Restricted stock unit expense                          |     |                |  — |     |              | — |     |                           |      47 |     |                                      |  — |     |                 |      — |   |     |                     | —        |   |     |                                       |     47 |   |
| Series A Preferred cash dividend                       |     |                |  — |     |              | — |     |                           |       — |     |                                      |  — |     |                 |      — |   |     |                     | (2       | ) |     |                                       |     (2 | ) |
| Series C Preferred stock dividend                      |     |                |  1 |     |              | — |     |                           |     173 |     |                                      |  — |     |                 |      — |   |     |                     | (173     | ) |     |                                       |      — |   |
| Loss for the period                                    |     |                |  — |     |              | — |     |                           |       — |     |                                      |  — |     |                 |      — |   |     |                     | (2,962   | ) |     |                                       | (2,962 | ) |
| Balance - September 30, 2023                           |     |                | 49 |     |              | 1 |     |                           | 141,856 |     |                                      | 21 |     |                 | 10,608 |   |     |                     | (154,512 | ) |     |                                       | (2,026 | ) |

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements. F-3 4

Kintara Therapeutics, Inc. Condensed Consolidated Interim Statements of Cash Flows (Unaudited) (In thousands)

|                                                                            |     |      |     | Three months endedSeptember 30, 
 2024                            |        |   |     | 2023 |        |   |
|:---------------------------------------------------------------------------|:----|-----:|:----|:--------------------------------|-------:|:--|:----|:-----|-------:|:--|
|